Part 3: Why p-Tau Matters: The Push to Better Measure Key Tau Proteoforms

As our understanding of tau biology has evolved, so too has the way researchers study and measure the protein. While tau was once viewed primarily as a structural component of neurons, it is now recognized as a dynamic protein that undergoes extensive post-translational modification (PTM), adopts multiple conformational states, and exists in a diverse spectrum of physiological and pathological forms. These molecular changes are increasingly central to how researchers investigate neurodegenerative disease. [1]

The first two blogs in our three-part series introduced tau’s role in normal neurophysiological function and how pathological changes in tau contribute to neurodegenerative disease states. This installment will outline why assessing disease-relevant tau species has become a major focus of biomarker discovery efforts and where gaps remain.

Moving Beyond Total Tau

For many years, total tau concentration served as one of the primary biomarkers used to study neurodegenerative disease. Elevated total tau concentrations in cerebrospinal fluid (CSF) are associated with neuronal injury and neurodegeneration, making the marker useful for identifying ongoing neurological damage. [2] However, total tau measurements provide limited information about the precise molecular processes driving disease.

Tau pathology is not simply defined by the abundance of the protein. Disease progression is associated with specific PTMs, changes in conformation, oligomerization, aggregation, and propagation of distinct pathological species. Consequently, two people with similar total tau levels may be experiencing substantially different disease states depending on the relative composition of tau species present. [3] As discussed in previous blogs, high phosphorylation and subsequent aggregation of tau have been established as pathological hallmarks of Alzheimer’s disease (AD) and other tauopathies. [4] This realization has driven a shift toward studying disease-associated p-tau species rather than total tau alone.

Among currently studied tau biomarkers, p-tau217 has gained traction as a clinically applicable AD biomarker. Multiple studies have demonstrated that plasma and CSF p-tau217 levels correlate closely with amyloid-β deposition and tau pathology while exhibiting high diagnostic accuracy for distinguishing AD from other neurodegenerative disorders. Importantly, elevated p-tau217 can be detected relatively early in disease progression, often before substantial cognitive impairment becomes apparent. [5] This has generated significant interest in p-tau217 as a potential tool for identifying patients in prodromal stages of Alzheimer's disease, supporting early clinical management as well as enrollment for therapeutic clinical trials. [6] The growing prominence of p-tau217 also reflects a broader shift in biomarker development toward markers that capture specific disease biology rather than generalized neuronal injury.

A Spectrum of Phospho-Tau Biomarkers

However, p-tau217 represents only one component of a complex biomarker landscape. Although several p-tau species have been associated with other tauopathies, including chronic traumatic encephalopathy (CTE) and progressive supranuclear palsy (PSP), the picture is most well-developed for AD. Most of the currently validated phospho-tau biomarkers are considered to be AD-specific, as their elevation correlates with in vivo clinical hallmarks of the disease as well as pathological hallmarks observed post-mortem.[7]

Some evidence suggests that p-tau231 may become abnormal particularly early in the disease process, while p-tau181 remains among the most extensively validated biomarkers across diverse patient populations. [8,9] Researchers are also investigating additional phosphorylation sites, including p-tau205 and p-tau212, which may provide insight into specific stages of disease progression or reflect distinct pathological mechanisms. [10,11] Rather than relying on a single biomarker, future approaches may increasingly leverage combinations of tau species to provide a more comprehensive picture of disease biology. [12] As the field continues to evolve, the ability to distinguish among closely related tau proteoforms will become increasingly important for understanding how different molecular events contribute to neurodegeneration.

Challenges in Measuring Phospho-Tau Species

As tau-directed therapeutic development accelerates, robust biomarker measurement has become increasingly important across the research continuum. In basic research, sensitive assays help investigators better understand the molecular events underlying tau pathology, including phosphorylation dynamics, aggregation pathways, and disease progression. Improved biomarker detection also enables more precise characterization of disease-relevant tau species in cellular and animal models. For drug developers, reliable biomarker assays are increasingly viewed as critical tools for clinical development. Biomarkers may support patient stratification, pharmacodynamic assessment, and longitudinal monitoring throughout clinical trials. [13] As therapies become more targeted toward specific pathogenic mechanisms, corresponding biomarker strategies must provide equally precise measurements.

Despite significant progress in tau biomarker research, accurately measuring phospho-tau species remains technically challenging. One major obstacle stems from the complexity of tau biology itself. Tau contains dozens of potential phosphorylation sites, many of which may occur simultaneously on the same molecule. The resulting diversity of proteoforms creates extensive analytical challenges, particularly when attempting to distinguish between closely related phosphorylated species that differ by only a single modification. [14]

Biological matrices further complicate measurement efforts. Tau concentrations in plasma are extremely low compared to other circulating proteins, increasing susceptibility to background interference and assay variability. [15] Matrix effects can influence antibody binding, signal generation, and overall assay performance, making it essential to validate biomarker measurements across relevant sample types. Sample collection methods, processing conditions, storage duration, freeze-thaw cycles, and handling procedures may also influence measured biomarker concentrations. [16] Even small inconsistencies can contribute to variability when detecting low-abundance analytes. These challenges underscore the importance of highly sensitive analytical methods and carefully validated detection reagents.

Empowering Research with Rigorous Assay Design and Validation

The value of any tau biomarker ultimately depends on the quality of the assay used to measure it. Antibody specificity is particularly important when detecting phospho-tau species. Because many phosphorylation sites exist within similar sequence contexts, antibodies must distinguish between highly related proteoforms while minimizing cross-reactivity with non-target species. [17] Even modest variations in specificity can lead to inaccurate quantification and misinterpretation of biological findings. Assay design also influences sensitivity, dynamic range, and performance in complex biological matrices. Antibodies and other reagents must generate reliable results across operators, laboratories, instruments, and time points, making rigorous validation processes essential.

As tau biomarker research continues to advance, assay quality will remain a critical determinant of scientific progress. Highly specific antibodies, well-validated assays, and robust analytical performance will help researchers more accurately characterize disease-relevant tau species, accelerate biomarker discovery, and support the development of next-generation therapeutics for Alzheimer's disease and related neurodegenerative disorders.

Aviva Systems Biology operates on the leading edge of these efforts, supporting researchers at every level with high-quality, comprehensively characterized and validated antibody reagents. Our broad portfolio includes total and phospho-tau ELISA kits with unmatched sensitivity and precision. To learn more about investigating tau and other neurodegenerative disease markers, download our eBook, ‘Neurodegenerative Disease Markers and Detection Methods.’ 

[1] Ossenkoppele, Rik, et al. “Tau Biomarkers in Alzheimer’s Disease: Towards Implementation in Clinical Practice and Trials.” The Lancet Neurology, vol. 21, no. 8, 2022, pp. 726–734. https://doi.org/10.1016/S1474-4422(22)00168-5.

[2] Hesse, C., et al. “Transient Increase in Total Tau but Not Phospho-Tau in Human Cerebrospinal Fluid after Acute Stroke.” Neuroscience Letters, vol. 297, no. 3, 2001, pp. 187–190. https://doi.org/10.1016/S0304-3940(00)01697-9.

[3] Schraen-Maschke, Susanna, et al. “Tau as a Biomarker of Neurodegenerative Diseases.” Biomarkers in Medicine, vol. 2, no. 4, 2008, pp. 363–384. https://doi.org/10.2217/17520363.2.4.363.

[4] Yang, Jiakai et al. “Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review.” Molecules (Basel, Switzerland) vol. 29,12 2812. 13 Jun. 2024, https://doi:10.3390/molecules29122812.

[5] Lai, Roy, et al. “P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease.” Biomedicines, vol. 12, no. 8, 2024, article 1836. https://doi.org/10.3390/biomedicines12081836.

[6] Mattsson-Carlgren, Niklas, et al. “Longitudinal Plasma p-tau217 Is Increased in Early Stages of Alzheimer’s Disease.” Brain: A Journal of Neurology, vol. 143, no. 11, 2020, pp. 3234–3241. https://doi.org/10.1093/brain/awaa286.

[7] Gonzalez-Ortiz, Fernando, et al. “Plasma Phospho-Tau in Alzheimer’s Disease: Towards Diagnostic and Therapeutic Trial Applications.” Molecular Neurodegeneration, vol. 18, no. 1, 2023, article 18. https://doi.org/10.1186/s13024-023-00605-8.

[8] Milà-Alomà, Marta, et al. “Plasma p-tau231 and p-tau217 as State Markers of Amyloid-β Pathology in Preclinical Alzheimer’s Disease.” Nature Medicine, vol. 28, no. 9, 2022, pp. 1797–1801, https://doi.org/10.1038/s41591-022-01925-w.

[9] Meng, Jie, and Peng Lei. “Plasma pTau181 as a Biomarker for Alzheimer’s Disease.” MedComm, vol. 1, no. 1, 2020, pp. 74–76. https://doi.org/10.1002/mco2.1.

[10] Kac, Przemysław R., et al. “Plasma p-tau212 Identifies Cognitively Unimpaired Individuals with Emerging Amyloid-β Pathology.” Journal of Neurology, vol. 273, no. 1, 2026, article 48, https://doi.org/10.1007/s00415-025-13572-5.

[11] Lantero-Rodriguez, Juan, et al. “CSF p-tau205: A Biomarker of Tau Pathology in Alzheimer’s Disease.” Acta Neuropathologica, vol. 147, no. 1, 2024, article 12, https://doi.org/10.1007/s00401-023-02659-w.

[12] Baek, Seungyeop, et al. “Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls.” Experimental Neurobiology, vol. 34, no. 1, 2025, pp. 1–8. https://doi.org/10.5607/en25008.

[13] Frost, Bess, et al. “Tau Biology, Biomarkers, and Therapeutics.” Alzheimer’s & Dementia: Translational Research & Clinical Interventions, vol. 11, no. 4, 2025, article e70165. https://doi.org/10.1002/trc2.70165.

[14] Cai, Qiyong, Mingsan Miao, and Zhaohui Li. “Advances and Emerging Challenges in Detecting Tau Proteoforms for Alzheimer’s Disease Diagnosis.” TrAC Trends in Analytical Chemistry, 2026, article 118897. https://doi.org/10.1016/j.trac.2026.118897.

[15] Triana-Baltzer, Gallen, et al. “Development and Validation of a High Sensitivity Assay for Measuring p217+tau in Cerebrospinal Fluid.” Journal of Alzheimer’s Disease, vol. 77, no. 4, 2020, pp. 1417–1430. https://doi.org/10.3233/JAD-200463.

[16] Espina, Virginia, et al. “Tissue Is Alive: New Technologies Are Needed to Address the Problems of Protein Biomarker Instability in Tissue Procurement.” Proteomics Clinical Applications, vol. 2, nos. 8–9, 2008, pp. 1097–1107. https://doi.org/10.1002/prca.200800001.

[17] Arbaciauskaite, Monika, Yu Lei, and Yong Ku Cho. “High-Specificity Antibodies and Detection Methods for Quantifying Phosphorylated Tau from Clinical Samples.” Antibody Therapeutics, vol. 4, no. 1, 2021, pp. 34–44. https://doi.org/10.1093/abt/tbab004.